S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
Critical asset just had biggest fall on record (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
U.S. "Shadow Banks" About to Blow up again? (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
U.S. "Shadow Banks" About to Blow up again? (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
Critical asset just had biggest fall on record (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
U.S. "Shadow Banks" About to Blow up again? (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
U.S. "Shadow Banks" About to Blow up again? (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
Critical asset just had biggest fall on record (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
U.S. "Shadow Banks" About to Blow up again? (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
U.S. "Shadow Banks" About to Blow up again? (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
Critical asset just had biggest fall on record (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
U.S. "Shadow Banks" About to Blow up again? (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
U.S. "Shadow Banks" About to Blow up again? (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies

Agios Pharmaceuticals (AGIO) Competitors

$32.99
+3.21 (+10.78%)
(As of 02/23/2024 ET)

AGIO vs. KNSA, DYN, PRTA, SAGE, KURA, PCRX, VRNA, SUPN, ABCL, and BLTE

Should you be buying Agios Pharmaceuticals stock or one of its competitors? The main competitors of Agios Pharmaceuticals include Kiniksa Pharmaceuticals (KNSA), Dyne Therapeutics (DYN), Prothena (PRTA), Sage Therapeutics (SAGE), Kura Oncology (KURA), Pacira BioSciences (PCRX), Verona Pharma (VRNA), Supernus Pharmaceuticals (SUPN), AbCellera Biologics (ABCL), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical preparations" industry.

Agios Pharmaceuticals vs.

Agios Pharmaceuticals (NASDAQ:AGIO) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk, community ranking and analyst recommendations.

In the previous week, Agios Pharmaceuticals had 13 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 17 mentions for Agios Pharmaceuticals and 4 mentions for Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals' average media sentiment score of 0.57 beat Agios Pharmaceuticals' score of -0.10 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Agios Pharmaceuticals
6 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kiniksa Pharmaceuticals
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Agios Pharmaceuticals currently has a consensus target price of $33.50, suggesting a potential upside of 1.55%. Kiniksa Pharmaceuticals has a consensus target price of $22.50, suggesting a potential upside of 12.50%. Given Kiniksa Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Kiniksa Pharmaceuticals is more favorable than Agios Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agios Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50
Kiniksa Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Kiniksa Pharmaceuticals has higher revenue and earnings than Agios Pharmaceuticals. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agios Pharmaceuticals$26.82M69.12-$352.09M-$6.34-5.20
Kiniksa Pharmaceuticals$248.75M5.66$183.36M-$0.11-181.82

Agios Pharmaceuticals received 317 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 67.85% of users gave Agios Pharmaceuticals an outperform vote while only 63.75% of users gave Kiniksa Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Agios PharmaceuticalsOutperform Votes
477
67.85%
Underperform Votes
226
32.15%
Kiniksa PharmaceuticalsOutperform Votes
160
63.75%
Underperform Votes
91
36.25%

Agios Pharmaceuticals has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500.

47.3% of Kiniksa Pharmaceuticals shares are held by institutional investors. 4.2% of Agios Pharmaceuticals shares are held by company insiders. Comparatively, 54.2% of Kiniksa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Kiniksa Pharmaceuticals has a net margin of -2.80% compared to Agios Pharmaceuticals' net margin of -1,312.64%. Kiniksa Pharmaceuticals' return on equity of -5.78% beat Agios Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Agios Pharmaceuticals-1,312.64% -38.08% -33.69%
Kiniksa Pharmaceuticals -2.80%-5.78%-4.96%

Summary

Kiniksa Pharmaceuticals beats Agios Pharmaceuticals on 11 of the 17 factors compared between the two stocks.


Get Agios Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGIO vs. The Competition

MetricAgios PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.85B$6.75B$5.11B$7.54B
Dividend YieldN/A2.74%2.86%3.87%
P/E Ratio-5.208.19167.7814.65
Price / Sales69.12193.873,049.1866.89
Price / CashN/A18.6198.6255.40
Price / Book2.294.604.394.60
Net Income-$352.09M$156.18M$113.02M$207.29M
7 Day Performance24.44%0.97%0.92%-1.07%
1 Month Performance53.37%10.70%7.29%3.58%
1 Year Performance31.38%3.86%10.68%5.52%

Agios Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KNSA
Kiniksa Pharmaceuticals
1.6511 of 5 stars
$19.86
-3.4%
$22.50
+13.3%
+49.7%$1.40B$220.18M-180.53220Upcoming Earnings
Gap Down
DYN
Dyne Therapeutics
2.9914 of 5 stars
$23.11
-4.9%
$33.00
+42.8%
+85.3%$1.42BN/A-6.44136Analyst Report
Insider Selling
Analyst Revision
News Coverage
PRTA
Prothena
3.8853 of 5 stars
$26.49
-10.0%
$68.25
+157.6%
-46.5%$1.42B$53.90M-18.65127Analyst Report
Analyst Revision
Gap Down
SAGE
Sage Therapeutics
3.5703 of 5 stars
$23.02
-3.4%
$41.50
+80.3%
-47.1%$1.38B$7.69M-2.10689Gap Down
KURA
Kura Oncology
3.4262 of 5 stars
$19.49
-4.5%
$28.28
+45.1%
+68.3%$1.45BN/A-9.65131Positive News
Gap Down
PCRX
Pacira BioSciences
4.2878 of 5 stars
$29.21
-2.7%
$51.44
+76.1%
-28.0%$1.36B$666.82M324.56715Upcoming Earnings
Analyst Revision
News Coverage
VRNA
Verona Pharma
0.5576 of 5 stars
$16.96
-1.4%
$32.60
+92.2%
-23.1%$1.36B$460,000.00-24.5835Upcoming Earnings
News Coverage
SUPN
Supernus Pharmaceuticals
4.5336 of 5 stars
$27.11
-4.4%
$43.00
+58.6%
-24.7%$1.48B$667.24M66.12612Upcoming Earnings
Positive News
Gap Down
ABCL
AbCellera Biologics
1.5833 of 5 stars
$5.11
-6.4%
$20.38
+298.7%
-42.8%$1.48B$485.42M-11.36630Analyst Report
Analyst Revision
News Coverage
BLTE
Belite Bio
1.2093 of 5 stars
$47.69
-0.5%
$44.83
-6.0%
+39.5%$1.32BN/A0.0016

Related Companies and Tools

This page (NASDAQ:AGIO) was last updated on 2/24/2024 by MarketBeat.com Staff